Nanjing Lizhi Enterprise Management Consulting Center (Limited Partnership) reduced its holdings in LEADS BIOLABS-B (09887) by 312,900 shares, with each share priced at approximately HKD 53.81.

The latest data from the Hong Kong Stock Exchange shows that on July 31, Nanjing Lizhi Enterprise Management Consulting Center (Limited Partnership) reduced its holdings in LEADS BIOLABS-B (09887) by 312,900 shares, at a price of HK$53.807 per share, totaling approximately HK$16.8362 million. After the reduction, the latest number of shares held is 30,375,920, representing a holding percentage of 15.37%. Additional information: Nanjing Lizhi Enterprise Management Consulting Center (Limited Partnership) ("Lizhi Partnership"), one of the corporations controlled by Dr. Kang Xiaoqiang, serves as one of the equity incentive platforms for Nanjing Weili Zhibo Biotechnology Co., Ltd. ("the Company"). On July 31, 2026, Lizhi Partnership sold a total of 312,900 shares that belong to company employees as directed by them. Dr. Kang Xiaoqiang did not reduce any of his personally held shares in the Company.